{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:17:07Z","timestamp":1790813827409,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1\/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1\/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations.<\/jats:p>\n                  <jats:p>Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984\u201398. \u00a92017 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Domchek, p. 937.<\/jats:p>\n                  <jats:p>See related article by Quigley et al., p. 999.<\/jats:p>\n                  <jats:p>See related article by Goodall et al., p. 1006.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 920<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-0419","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T20:20:13Z","timestamp":1496780413000},"page":"984-998","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":392,"title":["Secondary Somatic Mutations Restoring\n                    <i>RAD51C<\/i>\n                    and\n                    <i>RAD51D<\/i>\n                    Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma"],"prefix":"10.1158","volume":"7","author":[{"given":"Olga","family":"Kondrashova","sequence":"first","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Shield-Artin","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[{"name":"4British Columbia Cancer Agency, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson N.H.","family":"Teng","sequence":"additional","affiliation":[{"name":"5Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Harrell","sequence":"additional","affiliation":[{"name":"6University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kuiper","sequence":"additional","affiliation":[{"name":"7Melbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Yaw","family":"Ho","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia."},{"name":"8Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Barker","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jasin","sequence":"additional","affiliation":[{"name":"9Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Prakash","sequence":"additional","affiliation":[{"name":"9Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Kass","sequence":"additional","affiliation":[{"name":"9Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan R.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"10Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Brunette","sequence":"additional","affiliation":[{"name":"10Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara A.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"10Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"11The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[{"name":"12Institut Bergoni\u00e9, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[{"name":"13University of New South Wales and Prince of Wales Hospital, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"14Flinders University, Adelaide, South Australia, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[{"name":"15The Ohio State University, James Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[{"name":"16Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sun","sequence":"additional","affiliation":[{"name":"17Foundation Medicine, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Robillard","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Maloney","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bowtell","sequence":"additional","affiliation":[{"name":"18Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia."},{"name":"19Centre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Departments of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia."},{"name":"20QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Giordano","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Wakefield","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"7Melbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"21Mayo Clinic Cancer Center, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Simmons","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Harding","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Raponi","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"McNeish","sequence":"additional","affiliation":[{"name":"22Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[{"name":"6University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Lin","sequence":"additional","affiliation":[{"name":"3Clovis Oncology, Inc., Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia."},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia."},{"name":"8Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"2022060700562761500_bib1","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060700562761500_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022060700562761500_bib3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2022060700562761500_bib4","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022060700562761500_bib5","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2022060700562761500_bib6","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060700562761500_bib7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022060700562761500_bib8","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060700562761500_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022060700562761500_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"2022060700562761500_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"2022060700562761500_bib12","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060700562761500_bib13","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1158\/1078-0432.CCR-16-0247","article-title":"Biomarkers of response and resistance to DNA repair targeted therapies","volume":"22","author":"Stover","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022060700562761500_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"2022060700562761500_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J Pathol"},{"key":"2022060700562761500_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700562761500_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2022060700562761500_bib18","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2022060700562761500_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022060700562761500_bib20","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060700562761500_bib21","doi-asserted-by":"crossref","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2022060700562761500_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022060700562761500_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"key":"2022060700562761500_bib24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"key":"2022060700562761500_bib25","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","article-title":"Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors","volume":"289","author":"Joshi","year":"2014","journal-title":"J Biol Chem"},{"key":"2022060700562761500_bib26","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1093\/nar\/gkv101","article-title":"Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12\/CycK complex","volume":"43","author":"Ekumi","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2022060700562761500_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cancergencyto.2006.05.005","article-title":"RNA-based analysis of BRCA1 and BRCA2 gene alterations","volume":"170","author":"Bonatti","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"2022060700562761500_bib28","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1- 11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res"},{"key":"2022060700562761500_bib29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/nar\/gkl020","article-title":"Repression of mutagenesis by Rad51D-mediated homologous recombination","volume":"34","author":"Hinz","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"2022060700562761500_bib30","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Reports."},{"key":"2022060700562761500_bib31","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev"},{"key":"2022060700562761500_bib32","doi-asserted-by":"crossref","first-page":"41758","DOI":"10.1074\/jbc.M111.271080","article-title":"hSWS1\u2022SWSAP1 is an evolutionarily conserved complex required for efficient homologous recombination repair","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"2022060700562761500_bib33","doi-asserted-by":"crossref","first-page":"16443","DOI":"10.1074\/jbc.M001473200","article-title":"Evidence for simultaneous protein interactions between human Rad51 paralogs","volume":"275","author":"Schild","year":"2000","journal-title":"J Biol Chem"},{"key":"2022060700562761500_bib34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1534\/genetics.114.173518","article-title":"Evolutionary and functional analysis of the invariant SWIM domain in the conserved Shu2\/SWS1 protein family from Saccharomyces cerevisiae to Homo sapiens","volume":"199","author":"Godin","year":"2015","journal-title":"Genetics"},{"key":"2022060700562761500_bib35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","article-title":"Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts","volume":"8","author":"Topp","year":"2014","journal-title":"Mol Oncol"},{"key":"2022060700562761500_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2022060700562761500_bib37","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"2022060700562761500_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"2022060700562761500_bib39","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2022060700562761500_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21105\/joss.00018","article-title":"Xenomapper: mapping reads in a mixed species context","volume":"1","author":"Wakefield","year":"2016","journal-title":"JOSS"},{"key":"2022060700562761500_bib41","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2022060700562761500_bib42","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1101\/gr.137570.112","article-title":"Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer","volume":"22","author":"Ha","year":"2012","journal-title":"Genome Res"},{"key":"2022060700562761500_bib43","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1101\/gr.092759.109","article-title":"Circos: an information aesthetic for comparative genomics","volume":"19","author":"Krzywinski","year":"2009","journal-title":"Genome Research"},{"key":"2022060700562761500_bib44","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J Comput Chem"},{"key":"2022060700562761500_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nprot.2008.197","article-title":"Protein structure homology modeling using SWISS-MODEL workspace","volume":"4","author":"Bordoli","year":"2009","journal-title":"Nat Protocols"},{"key":"2022060700562761500_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nsmb795","article-title":"Crystal structure of a Rad51 filament","volume":"11","author":"Conway","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"2022060700562761500_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graph"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/9\/984\/1847193\/984.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/9\/984\/1847193\/984.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:57:03Z","timestamp":1654549023000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/9\/984\/6165\/Secondary-Somatic-Mutations-Restoring-RAD51C-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,8,31]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0419","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22532014.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532008.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546607.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}